title: [Role of matrix metalloproteinase-9 in the pathogenesis of osteoporosis in patients with chronic obstructive pulmonary disease].
abstract: OBJECTIVE
  To determine a relationship between matrix metalloproteinase-9 (MMP-9) activity and its tissue inhibitors TIMP-1 and 2, tumor necrosis factor-alpha (TNF-alpha), bone mineral density (BMD), and bone exchange in chronic obstructive pulmonary disease (COPD).
  
  
  METHODS
  Seventy-six patients with COPD and 20 healthy volunteers were examined using dual-energy X-ray absorptiometry n the lumbar spine (L(II)-L(IV)) and femoral neck (FN). The serum levels of MMP-9, TIMP-1 and TIMP-2, TNF-alpha, and beta-Crosslaps (betaCL) were measured.
  
  
  RESULTS
  There was a higher MMP-9 level in COPD than that in the controls ((383.8 +/- 54.2 and 137.6 +/- 31.4 pg/ml, respectively; p < 0.01). The levels of TIMP-1 and TIMP-2 were not different from those in the control group. An inverse correlation was found between forced expiratory volume in one second (FEV1) and MMP-9 concentration (r = -0.59; p = 0.002) and a positive correlation with smoking index (r = 0.47; p = 0.04). There was an inverse correlation between MMP-9 concentration and BMD in both L(II)-L(IV) and FN (r = -0.67; p < 0.001 and r = -0.61; p < 0.01, respectively) and a direct correlation with betaCL (r = 0.53; p = 0.04). An inverse correlation was established between TNF-alpha and T index in both L(II)-L(IV) (r = -0.54; p < 0.01) and FN (r = -0.48; p < 0.01). At the same time, the level of TNF-alpha directly correlated with the bone resorption marker betaCL (r = 0.53; p = 0.002) and MMP-9 (r = 0.57; p = 0.003).
  
  
  CONCLUSIONS
  Elevated MMP-9 levels may play an important role in type I collagen degradation, giving rise to enhanced bone resorption in COPD.
authors.forename: E A
authors.initials: EA
authors.lastname: Kochetkova
authors.forename: L G
authors.initials: LG
authors.lastname: Ugaĭ
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Maĭstrovskaia
authors.forename: K A
authors.initials: KA
authors.lastname: Buria
authors.forename: V A
authors.initials: VA
authors.lastname: Nevzorova
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000502:physiology*; D061965:Matrix Metalloproteinase Inhibitors; D008875:Middle Aged; D010024:Osteoporosis / Q000175:diagnosis / Q000201:enzymology* / Q000209:etiology; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000175:diagnosis / Q000201:enzymology*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000502:physiology; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000378:metabolism
chemical_list: D061965:Matrix Metalloproteinase Inhibitors; C560822:TIMP1 protein, human; C560823:TIMP2 protein, human; D019715:Tissue Inhibitor of Metalloproteinase-1; D019716:Tissue Inhibitor of Metalloproteinase-2; D020780:Matrix Metalloproteinase 9